ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Stronger Together: ALK+ (Virtual) Summit 2021 July 31 & Aug 1
TWO AMAZING DAYS of Knowledge, Hope, Sharing & Connection REGISTRATION IS FREE! DAY 1_SATURDAY AGENDA: (All times Eastern Standard)10:00am-11:00am (EST) Welcome! We are kicking off our ALK Summit 2021 with our ALK Summit Chair Amanda Nerstad, President Gina Hollenbeck and our keynote speaker, Teresa Graham, Head of Global Product Strategy with Roche Pharmaceuticals 11:15am-12:45am The…
-
Dr. Benjamin Levy & NPC Rasheda Persinger join ALKtALK
BENJAMIN PHILLIP LEVY, MD, Clinical Director of Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Associate Professor of Oncology RASHEDA PERSINGER, Nurse Practitioner Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Deborah Kimmel, a patient since January 2018, gave an introduction. “Dr. Levy is one of the leading Thoracic…
-
ALK Genetics 101
About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to…
-
Hope for ALK+ NSCLC Patients
It’s important that we generate our own hope throughout the challenges and difficulties of ALK+ NSCLC. Oh yes, there is plenty to be hopeful about on the research and treatment fronts. The news about next-generation TKIs, chemotherapy, vaccines, a variety of promising trials; all give credence to the case for much longer survival than ever. …
-
Update on Clinical Trials currently recruiting for ALK-positive lung cancer
A new ALK inhibitor starts its clinical trials this month! TPX-0131 is an TKI ALK inhibitor designed to overcome multiple ALK resistance mutations. This first-in-human trial for ALK-positive lung cancer is now recruiting near Perth, Australia. Other sites for the FORGE-1 trial will be added in Australia and the U.S. over the next few months.…
-
Real World Data in Medical Research
What is real world data vs. on-paper data? Scientists create experiments in laboratories and present the best data they can in published papers for everyone to share. That’s paper data. In real life, clinical doctors prescribe the medication and the end results for people are the real-world data. Most of the time, this section highlights…
-
Dr. Justin Gainor & Dr. Aaron Hata join ALKtALK
Dr. Justin Gainor, MD Director of Center for Thoracic Cancers & Director of Targeted Immunotherapy at Massachusetts General Hospital, Boston Assistant Professor of Medicine at Harvard Medical School “It’s great to be here tonight. It’s so nice to see so many familiar faces on the call. Being one of the recipients for the ALK Positive…
-
Hydration Dos & Don’ts
Hydration talk. When I am sick, I always seek out a bowl of “chicken noodle soup.” In every culture, there’s always something soothing, whether it is a stew, soup, or something more substantial when you are feeling down. It works because these types of food can give you the essential nutrition you need when you…
-
Dr. Mark Awad & Dr. Roberto Chiarle join ALKtALK
Mark Awad, MD, PhD Clinical Director, Thoracic Oncology Treatment Center Assistant Professor of Medicine, Harvard Medical School I hope everyone is safe, warm, and healthy tonight. I am the Clinical Director of Thoracic Oncology at Dana Farber Cancer Institute in Boston, MA. I did Medical School at John’s Hopkins, medical residency at Mass General, and…
-
Ensartinib: the unknown TKI
Ensartinib (x396) is a medicine made by Xcovery, a biotech company based in Florida. It works closely with another company called Betta Pharmaceuticals in China for many of its trials. Currently, there is an eXalt3 (phase 3) clinical trial to compare Ensartinib against Xalkori (not currently recruiting). Originally, there was a phase1/2 trial done in…
-
Dr. Jessica Lin and Dr. Ibiayi Dagogo-Jack join ALKtALK
Dr. Jessica Lin Attending physician, Hematology/Oncology, Massachusetts General Hospital Instructor, Medicine, Harvard Medical School Dr. Lin: I first began interested in oncology in my undergraduate years. I started out as a biochemist, but I met a mentor who was a pediatric oncologist who also worked in basic research. He really inspired me and made me…